Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy

July 18th 2022

Dr Charu Aggarwal shares data from the IMpower133 trial of atezolizumab plus chemotherapy for SCLC, and how to select the appropriate frontline therapy.

Dr. Brahmer on the Examination of Nemvaleukin Alfa in Solid Tumors

July 16th 2022

Julie R. Brahmer, MD, MSc, discusses the examination of nemvaleukin alfa in solid tumors.

Advanced NSCLC: The Advent of Frontline IO Monotherapy

July 15th 2022

Focusing on single-agent immunotherapy in advanced NSCLC, experts review key data from the KEYNOTE-024, IMpower110, and EMPOWER-Lung 1 clinical trials.

Paradigm for Immunotherapy in Advanced Non-Small Cell Lung Cancer

July 15th 2022

Expert oncologists review the current state of molecular testing and PD-L1 expression in the setting of advanced non–small cell lung cancer management.

Trilaciclib Efficacy in the Prevention of CIM in ES-SCLC

July 15th 2022

Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.

Myeloprotective Benefit of CDK4/6 Inhibition in ES-SCLC

July 15th 2022

Edgardo Santos, MD, FACP, and Martin Dietrich, MD, PhD, share insights into the mechanism of action of CDK4/6 inhibitors for the prevention of myelosuppression in ES-SCLC.

Dr. Peled on the Rationale of Evaluating Lenvatinib/Pembrolizumab with Chemotherapy in NSCLC

July 13th 2022

Nir Peled, MD, PhD, FCCP, discusses the rationale of evaluating the combination of lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.

ADC Technology and Mechanism of Action

July 13th 2022

Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.

Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer

July 13th 2022

Dr Levy presents updated safety and efficacy results on larotrectinib in patients with TRK fusion-positive lung cancer.

Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer

July 13th 2022

Dr Benjamin Levy reviews long-term, pooled safety and efficacy data on larotrectinib in patients with TRK fusion-positive cancers.

Selecting Appropriate Adjuvant Chemotherapy for Early-Stage NSCLC

July 12th 2022

Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.

Treatment for Early-Stage NSCLC: Resection and Adjuvant Radiation Therapy

July 12th 2022

Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.

Management of Adverse Events Associated with Durvalumab + Chemotherapy

July 11th 2022

Vivek Subbiah, MD, analyzes adverse events observed with durvalumab plus chemotherapy in patients with SCLC and how they can be managed.

Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy

July 11th 2022

Jared Weiss, MD, reviews data from the CASPIAN trial of durvalumab plus chemotherapy in patients with extensive-stage small cell lung cancer.

Prophylactic Approaches to the Management of CIM in ES-SCLC

July 8th 2022

Expert panelists review considerations in the prophylactic treatment of chemotherapy-induced myelosuppression with special attention paid to unmet needs related to the use of G-CSF and ESAs.

An Overview of Chemotherapy-Induced Myelosuppression in ES-SCLC

July 8th 2022

Two leaders in the management of ES-SCLC provide an overview of chemotherapy-induced myelosuppression including key risk factors and its effect on patient outcomes.

Future Implications of ctDNA in the Management of NSCLC

July 7th 2022

A thoracic oncology expert provides perspective on ctDNA as a tool and its future as part of the NSCLC landscape.

Review of Recent Data on ctDNA From ASCO 2022

July 7th 2022

A comprehensive review of data presented at ASCO 2022 on ctDNA and MRD detection in NSCLC.

Two Key Uses for ctDNA in the Clinical Setting

July 7th 2022

Dr. Mark Kris shares insight on ctDNA and its use in detecting MRD in NSCLC.

Strategies for Monitoring Patients with NSCLC

July 7th 2022

Practical advice on monitoring options for patients with NSCLC treated with definitive radiation therapy or surgery.